DAVITA INC.
DVAAPI behind this page
DVA Q2 2025 request
Playground key active
/api/financials?ticker=DVA&year=2025&quarter=2
Pick an endpoint and run the request.Income Statement
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Revenue From Contract With Customer Including Assessed Tax Net Of Provision For Uncollectible Accounts | 3,206,871 | 3,061,102 | +4.8% |
| Other Income | 172,655 | 125,620 | +37.4% |
Show Business Segments breakouts |
|||
| All Other Segments · Commercial Payors | 8,322 | 10,200 | -18.4% |
| All Other Segments · Medicare and Medicare Advantage | 140,149 | 97,433 | +43.8% |
| All Other Segments · Other | 21,054 | 15,467 | +36.1% |
| Other Operating Segments with Intersegment · Operating Segments | 166,689 | 119,722 | +39.2% |
| U S Dialysis And Related Lab Services with Intersegment · Operating Segments | 5,966 | 5,898 | +1.2% |
| U. S. Dialysis And Related Lab Services · Other | 5,966 | 5,898 | +1.2% |
Show Health Care Organization Revenue Sources breakouts |
|||
| Commercial Payors | 8,322 | 10,200 | -18.4% |
| Medicare and Medicare Advantage | 140,149 | 97,433 | +43.8% |
| Other | 27,020 | 21,365 | +26.5% |
| Revenue | 3,379,526 | 3,186,722 | +6.1% |
Show Business Segments breakouts |
|||
| All Other Segments | 482,851 | 358,637 | +34.6% |
| All Other Segments · Intersegment Elimination | -2,836 | -3,823 | +25.8% |
| Other Operating Segments with Intersegment · Operating Segments | 485,687 | 362,460 | +34.0% |
| U S Dialysis And Related Lab Services with Intersegment · Operating Segments | 2,913,391 | 2,841,010 | +2.5% |
| U. S. Dialysis And Related Lab Services | 2,896,675 | 2,828,085 | +2.4% |
| U. S. Dialysis And Related Lab Services · Intersegment Elimination | -16,716 | -12,925 | -29.3% |
Show Consolidation Items breakouts |
|||
| Intersegment Elimination | -19,552 | -16,748 | -16.7% |
| Operating Segments | 3,399,078 | 3,203,470 | +6.1% |
| Patient Care Costs | 2,261,540 | 2,142,299 | +5.6% |
Show Business Segments breakouts |
|||
| U. S. Dialysis And Related Lab Services · Operating Segments | 1,928,462 | 1,854,541 | +4.0% |
| General & Administrative | 412,805 | 367,845 | +12.2% |
Show Business Segments breakouts |
|||
| U. S. Dialysis And Related Lab Services · Operating Segments | 312,089 | 281,795 | +10.8% |
| Depreciation And Amortization | 174,704 | 175,661 | -0.5% |
Show Business Segments breakouts |
|||
| All Other Segments | 17,923 | 15,251 | +17.5% |
| U. S. Dialysis And Related Lab Services | 156,782 | 160,410 | -2.3% |
| Income Loss From Equity Method Investments | -7,364 | -5,481 | -34.4% |
| Total Costs & Expenses | 2,841,685 | 2,680,324 | +6.0% |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 428,973 | 381,052 | +12.6% |
| U. S. Dialysis And Related Lab Services · Operating Segments | 2,390,547 | 2,290,824 | +4.4% |
| Operating Income | 537,841 | 506,398 | +6.2% |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 56,714 | -18,592 | +405.0% |
| U. S. Dialysis And Related Lab Services · Operating Segments | 522,844 | 550,186 | -5.0% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 579,558 | 531,594 | +9.0% |
| Interest And Debt Expense | -146,062 | -97,747 | -49.4% |
| Other Non-Operating Income (Expense) | -22,851 | -27,479 | +16.8% |
| Income Before Taxes | 368,928 | 371,440 | -0.7% |
| Income Tax Expense (Benefit) | 93,708 | 71,688 | +30.7% |
| Net Income | 275,220 | 299,752 | -8.2% |
| Net Income Loss Attributable To Noncontrolling Interest | -75,883 | -77,076 | +1.5% |
| Net Income | 199,337 | 222,676 | -10.5% |
| EPS (Basic) | 2.62 | 2.56 | +2.3% |
| EPS (Diluted) | 2.58 | 2.5 | +3.2% |
| Wtd Avg Shares (Basic) | 75,943 | 86,899 | -12.6% |
| Wtd Avg Shares (Diluted) | 77,362 | 88,950 | -13.0% |
| Comprehensive Income | 288,467 | 127,701 | +125.9% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax | -6,405 | 5,919 | -208.2% |
| Revenue From Contract With Customer Including Assessed Tax (Q) | — | — | — |
Show Business Segments breakouts |
|||
| All Other Segments · Commercial Payors | 91,225 | 62,391 | +46.2% |
| All Other Segments · Other Government Payors | 224,937 | 176,524 | +27.4% |
| Other Operating Segments with Intersegment · Operating Segments | 316,162 | 238,915 | +32.3% |
| Other Operating Segments with Intersegment · Operating Segments | 2,836 | 3,823 | -25.8% |
| U S Dialysis And Related Lab Services with Intersegment · Operating Segments | 2,907,425 | 2,835,112 | +2.6% |
| U S Dialysis And Related Lab Services with Intersegment · Operating Segments | 2,890,709 | 2,822,187 | +2.4% |
| U S Dialysis And Related Lab Services with Intersegment · Operating Segments | 16,716 | 12,925 | +29.3% |
| U. S. Dialysis And Related Lab Services · Commercial Payors | 947,015 | 952,625 | -0.6% |
| U. S. Dialysis And Related Lab Services · Medicaid and Managed Medicaid | 217,699 | 214,951 | +1.3% |
| U. S. Dialysis And Related Lab Services · Medicare and Medicare Advantage | 1,659,607 | 1,587,198 | +4.6% |
| U. S. Dialysis And Related Lab Services · Other Government Payors | 83,104 | 80,338 | +3.4% |
Show Health Care Organization Revenue Sources breakouts |
|||
| Commercial Payors | 1,038,240 | 1,015,016 | +2.3% |
| Medicaid and Managed Medicaid | 217,699 | 214,951 | +1.3% |
| Medicare and Medicare Advantage | 1,659,607 | 1,587,198 | +4.6% |
| Other Government Payors | 308,041 | 256,862 | +19.9% |
Balance Sheet
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 708,417 | 416,493 | +70.1% |
| Marketable Securities (Current) | 31,014 | 20,693 | +49.9% |
| Accounts Receivable | 2,441,259 | 2,303,119 | +6.0% |
| Inventory | 146,295 | 126,765 | +15.4% |
| Other Receivables Net Current | 477,191 | 420,623 | +13.4% |
| Prepaid Expenses & Other Current Assets | 110,334 | 83,106 | +32.8% |
| Total Current Assets | 4,087,828 | 3,466,925 | +17.9% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 2,854,468 | 2,982,222 | -4.3% |
| Operating Lease Right-of-Use Assets | 2,338,599 | 2,457,565 | -4.8% |
| Marketable Securities (Non-Current) | 38,722 | 31,779 | +21.8% |
| Other Non-Current Assets | 192,749 | 240,490 | -19.9% |
| Goodwill | 7,465,769 | — | — |
Show Business Segments breakouts |
|||
| All Other Segments | 943,165 | — | — |
| U. S. Dialysis | 6,522,604 | — | — |
| Total Assets | 17,492,958 | 17,025,572 | +2.7% |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | 593,868 | 343,772 | +72.8% |
| Other Assets | |||
| Restricted Cash And Cash Equivalents | 88,542 | 86,753 | +2.1% |
| Income Taxes Receivable | 84,776 | 9,373 | +804.5% |
| Intangible Assets Net Excluding Goodwill | 211,687 | 191,483 | +10.6% |
| Investments In Affiliates Subsidiaries Associates And Joint Ventures | 303,136 | — | — |
| Current Liabilities | |||
| Accounts Payable | 594,403 | 493,534 | +20.4% |
| Other Liabilities Current | 921,174 | 888,358 | +3.7% |
| Employee Related Liabilities Current | 686,242 | 644,865 | +6.4% |
| Operating Lease Liability Current | 429,252 | 404,820 | +6.0% |
| Long Term Debt And Capital Lease Obligations Current | 182,442 | 537,991 | -66.1% |
| Accrued Income Taxes Current | 19,691 | 25,222 | -21.9% |
| Total Current Liabilities | 2,933,540 | 2,994,790 | -2.0% |
| Non-Current Liabilities | |||
| Operating Lease Liabilities | 2,124,875 | 2,281,372 | -6.9% |
| Other Non-Current Liabilities | 156,486 | 179,010 | -12.6% |
| Deferred Tax Liabilities | 646,229 | 693,982 | -6.9% |
| Total Liabilities | 15,939,935 | 14,600,716 | +9.2% |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | 247,330 | 157,627 | +56.9% |
| Other Liabilities | |||
| Due To Related Party | 100,336 | — | — |
Show Related Party Transaction breakouts |
|||
| Principal Owner | 100,336 | — | — |
| Long Term Debt And Capital Lease Obligations | 10,078,805 | 8,451,562 | +19.3% |
| Stockholders' Equity | |||
| Common Stock | 91 | 90 | +1.1% |
| Additional Paid In Capital Common Stock | 356,884 | 383,235 | -6.9% |
| Retained Earnings | 1,896,884 | 1,060,613 | +78.8% |
| Treasury Stock Value | -2,485,654 | -615,948 | -303.5% |
| Accumulated Other Comprehensive Income | -137,838 | — | — |
| Total Stockholders' Equity | -369,633 | 632,900 | -158.4% |
| Minority Interest | 261,666 | 217,116 | +20.5% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -107,967 | 850,016 | -112.7% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -137,838 | -195,090 | +29.3% |
| Additional Paid In Capital | 356,884 | 383,235 | -6.9% |
| Common Stock | 91 | 90 | +1.1% |
| Noncontrolling Interest | 261,666 | 217,116 | +20.5% |
| Parent | -369,633 | 632,900 | -158.4% |
| Retained Earnings | 1,896,884 | 1,060,613 | +78.8% |
| Treasury Stock Common | -2,485,654 | -615,948 | -303.5% |
| Total Liabilities & Equity | 17,492,958 | 17,025,572 | +2.7% |
| Treasury Stock Common Shares | 16,560 | — | — |
Show Equity Components breakouts |
|||
| Treasury Stock Common | -16,560 | -4,774 | -246.9% |
| Common Stock Par Or Stated Value Per Share | 0 | — | — |
| Common Stock Shares Authorized | 450,000 | — | — |
| Redeemable Noncontrolling Interest Equity Carrying Amount | 1,660,990 | 1,574,840 | +5.5% |
Cash Flow Statement
| Metric | YTD Q2 2025 | YTD Q2 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation Amortization And Accretion Net | 351,155 | 362,744 | -3.2% |
| Stock-Based Compensation | 62,567 | 48,832 | +28.1% |
| Deferred Income Taxes | -9,838 | -28,643 | +65.7% |
| Adjustment Income Loss From Equity Method Investments | 47,730 | 54,748 | -12.8% |
| Other Non-Cash Items | 6,948 | 16,570 | -58.1% |
| Change in Accounts Receivable | -288,447 | -193,093 | -49.4% |
| Change in Inventory | -9,592 | 22,422 | -142.8% |
| Increase Decrease In Other Current Receivables And Other Current Assets | -70,945 | -13,898 | -410.5% |
| Increase Decrease In Other Noncurrent Assets | 2,981 | -3,367 | +188.5% |
| Change in Accounts Payable | 35,612 | -38,998 | +191.3% |
| Increase Decrease In Employee Related Liabilities | -125,365 | -122,817 | -2.1% |
| Increase Decrease In Other Current Liabilities | -3,586 | 1,219 | -394.2% |
| Increase Decrease In Accrued Income Taxes Payable | 9,462 | -8,097 | +216.9% |
| Change in Other Liabilities | -11,873 | -6,642 | -78.8% |
| Net Cash from Operations | 504,245 | 664,010 | -24.1% |
| Investing Activities | |||
| Capital Expenditures | -264,349 | -245,740 | -7.6% |
| Payments To Acquire Businesses Gross | -10,596 | -157,783 | +93.3% |
| Proceeds From Sales Of Business Affiliate And Productive Assets | 22,400 | 12,779 | +75.3% |
| Payments To Acquire Held To Maturity Securities | -27,475 | -309 | -8791.6% |
| Payments To Acquire Other Investments | -3,002 | -3,411 | +12.0% |
| Proceeds From Sale And Maturity Of Held To Maturity Securities | 48,014 | 7,082 | +578.0% |
| Proceeds From Sale And Maturity Of Other Investments | 6,379 | 4,564 | +39.8% |
| Payments To Acquire Equity Method Investments | -2,144 | -700 | -206.3% |
| Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital | 1,470 | 6,554 | -77.6% |
| Net Cash from Investing | -229,303 | -376,964 | +39.2% |
| Financing Activities | |||
| Proceeds From Issuance Of Long Term Debt | 4,189,716 | 3,275,533 | +27.9% |
| Repayments Of Debt And Capital Lease Obligations | -3,373,300 | -2,661,145 | -26.8% |
| Payments Of Financing Costs | -25,133 | -19,993 | -25.7% |
| Purchase Of Treasury Stock From Related Party | -200,261 | — | — |
| Share Repurchases | -793,834 | -612,614 | -29.6% |
| Payments Of Distributions To Affiliates | -151,087 | -107,210 | -40.9% |
| Net Proceeds From Issuance Of Stock To Employees | 8,913 | 7,421 | +20.1% |
| Tax Withholding for Share Compensation | -30,477 | -93,698 | +67.5% |
| Proceeds From Contributions From Affiliates | 2,578 | 7,621 | -66.2% |
| Proceeds From Minority Shareholders | 169 | 860 | -80.3% |
| Payments To Minority Shareholders | -5,378 | -40,751 | +86.8% |
| Net Cash from Financing | -378,094 | -243,976 | -55.0% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 20,286 | -4,458 | +555.0% |
| Net Change in Cash | -82,866 | 38,612 | -314.6% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 796,959 | 503,246 | +58.4% |
Values in thousands USD. Source: SEC EDGAR 10-Q filing.